Skip to content
The Policy VaultThe Policy Vault

TasmarMedica

Parkinson’s disease

Preferred products

  • entacapone
  • Ongentys (opicapone capsules)

Initial criteria

  • Patient is currently receiving carbidopa/levodopa therapy
  • Patient has tried an entacapone product or Ongentys (opicapone capsules) and meets ONE of the following: i) According to the prescriber, patient had significant intolerance; OR ii) According to the prescriber, patient had inadequate efficacy
  • Medication is prescribed by or in consultation with a neurologist

Approval duration

1 year